A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

BJU International

Volumn 109, Issue 10, 2012, Pages 1495-1502

  Nobes, Jenny P ^a   Langley, Stephen E M ^a   Klopper, Tanya ^a   Russell Jones, David ^a   Laing, Robert W ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

androgen deprivation therapy; insulin resistance; metabolic syndrome X; metformin; prostatic neoplasms

Indexed keywords

BICALUTAMIDE; GOSERELIN; LEUPRORELIN; METFORMIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANTHROPOMETRY; ARTICLE; BODY MASS; BRACHYTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; EXERCISE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MALE; METABOLIC SYNDROME X; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BEHAVIOR THERAPY; BLOOD GLUCOSE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84860351010     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10555.x     Document Type: Article

References (39)

1. Pilepich MV, Winter K, John MJ, et al,. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
2. Pilepich MV, Winter K, Lawton CA, et al,. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90
3. Bolla M, Collette L, Blank L, et al,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
4. Hanks GE, Lu JD, Machtay M, et al,. RTOG protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000; 48: 112
5. Nobes JP, Wells IG, Khaksar SJ, Money-Kyrle JF, Laing RW, Langley SE,. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience. Prostate Cancer Prostatic Dis 2009; 12: 61-6
6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D,. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
7. Brown BW, Brauner C, Minnotte MC,. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 1993; 85: 979-87
8. Satariano WA, Ragland KE, Van Den Eeden SK,. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83: 1180-8
9. Lu-Yao G, Stukel TA, Yao SL,. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004; 171: 2285-90
10. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56
11. D'Amico AV, Denham JW, Crook J, et al,. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5
12. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR,. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-24
13. Alibhai SM, Duong-Hua M, Sutradhar R, et al,. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-8
14. Braga-Basaria M, Dobs AS, Muller DC, et al,. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83
15. Nobes JP, Langley SE, Laing RW,. Metabolic syndrome and prostate cancer: a review. Clin Oncol (R Coll Radiol) 2009; 21: 183-91
16. Cancer Research UK. CancerStats-Key Facts. Prostate Cancer. Available at:. Accessed February 2010
17. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC,. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006; 98: 973-8
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE,. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163: 2594-602
19. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE,. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4: CD002967
20. Jenkins DJ, Wolever TM, Taylor RH, et al,. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981; 34: 362-6
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
22. Levy JC, Matthews DR, Hermans MP,. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2
23. Office for National Statistics. Mortality Statistics: Cause, England & Wales 2006. Series DH2. London: Stationery Office, 2008
24. ISD Scotland. Cancer Mortality. 2008. Available at:. Accessed February 2010
25. Northern Ireland Cancer Registry. Cancer Incidence and Mortality in Northern Ireland, 2006. Available at:. Accessed February 2010
26. Reaven GM,. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
27. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT,. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-23
28. Laaksonen DE, Niskanen L, Punnonen K, et al,. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41
29. Smith JC, Bennett S, Evans LM, et al,. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261-7
30. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS,. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-8
31. Eckel RH, Grundy SM, Zimmet PZ,. The metabolic syndrome. Lancet 2005; 365: 1415-28
32. Ford ES, Giles WH, Dietz WH,. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9
33. Orchard TJ, Temprosa M, Goldberg R, et al,. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-9
34. Knowler WC, Fowler SE, Hamman RF, et al,. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-86
35. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5
36. Jiralerspong S, Palla SL, Giordano SH, et al,. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-302
37. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ,. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176: 520-5
38. Smith MR, Malkowicz SB, Chu F, et al,. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008; 26: 1824-9
39. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8